Calamos Wealth Management LLC Sells 6,096 Shares of Johnson & Johnson $JNJ

Key Points

• Calamos Wealth Management reduced its Johnson & Johnson stake by 4.8% in the first quarter, selling 6,096 shares and leaving it with 120,952 shares valued at about $29.6 million.
• Johnson & Johnson beat quarterly expectations, reporting EPS of $2.90 on revenue of $25.31 billion, while raising FY 2026 guidance to $11.60-$11.75 EPS and about $100.8 billion-$101.4 billion in revenue.
• The company also reaffirmed its income appeal by declaring a quarterly dividend of $1.34 per share, equal to $5.36 annually and a yield of 2.2%.

Calamos Wealth Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 120,952 shares of the company's stock after selling 6,096 shares during the quarter. Johnson & Johnson comprises 1.0% of Calamos Wealth Management LLC's portfolio, making the stock its 18th largest position. Calamos Wealth Management LLC's holdings in Johnson & Johnson were worth $29,565,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. State Street Corp raised its stake in Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock valued at $27,704,364,000 after buying an additional 1,663,782 shares during the last quarter. Auto Owners Insurance Co raised its stake in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock worth $11,967,947,000 after acquiring an additional 1,738,292 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $6,924,523,000. Institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ opened at $247.55 on Thursday. The company's 50 day moving average is $238.64 and its 200 day moving average is $234.20. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The company has a market cap of $595.90 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.42 and a beta of 0.24. Johnson & Johnson has a 12-month low of $159.80 and a 12-month high of $269.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.02 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 61.97%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Daiwa Securities Group lifted their price target on Johnson & Johnson from $237.00 to $246.00 and gave the stock an "outperform" rating in a research report on Thursday, April 16th. Weiss Ratings lowered shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b-)" rating in a research note on Monday, June 15th. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a report on Wednesday, April 15th. Guggenheim upped their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, June 26th. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $283.00 to $284.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $261.70.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ beat Q2 estimates, with EPS of $2.90 and revenue of $25.31 billion, helped by strong pharmaceutical growth from Darzalex, Tremfya and Spravato. Reuters article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $11.60-$11.75 and revenue of about $100.8 billion-$101.4 billion, signaling management confidence in continued growth. Business Wire article
• Positive Sentiment: Jefferies highlighted Spravato’s strong sales growth as a positive read-through for the broader psychedelic/depression-treatment market, reinforcing the value of J&J’s innovative medicines franchise. Proactive Investors article
• Positive Sentiment: Unusual options activity leaned bullish, with traders buying more JNJ call options than usual, suggesting some expectations for upside after earnings.
• Neutral Sentiment: Johnson & Johnson declared a quarterly dividend of $1.34 per share, underscoring its shareholder-return profile and dividend-king status.
• Neutral Sentiment: Stifel maintained a Hold rating with a $260 price target, reflecting a balanced view after the earnings report. TipRanks article
• Negative Sentiment: Despite the beat-and-raise quarter, the stock slipped because investors appeared underwhelmed relative to elevated expectations and are still weighing MedTech softness and talc-related legal risk. MarketBeat article

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.